The Asia Pacific Automated Cell Counting Market would witness market growth of 13.0% CAGR during the forecast period (2023-2030).
Technological innovation serves as the bedrock of this market's growth. Advancements in imaging technologies, microfluidics, artificial intelligence, and multiplexing capabilities continuously elevate these instruments' precision, speed, and capabilities. The COVID-19 pandemic acted as a catalyst, underscoring the indispensable role of cell analysis in virology, vaccine development, and immunology research. It also accelerated the adoption of remote monitoring and automated solutions, further highlighting the adaptability and resilience of these instruments in demanding and dynamic research environments.
Emerging trends such as integrating artificial intelligence (AI) and machine learning in cell analysis, miniaturization of instruments for point-of-care testing, and increased focus on personalized medicine further expand the market's scope, opening new opportunities for innovation and growth. AI algorithms in image-based cell measuring instruments improve accuracy by precisely identifying and counting cells, overcoming challenges related to variations in cell morphology and background noise.
The pharmaceutical industry's expanding emphasis on target research and drug discovery increases the need for automated cell counters. Preclinical lab testing of novel drug candidates and vaccines is essential to these systems. Numerous prominent pharmaceutical companies are implementing automated solutions to decrease drug development costs and schedules while accelerating their R D programs. Thus, the demand for automated cell counting systems is propelled by advancements in this region's pharmaceutical and biotechnology industries.
The China market dominated the Asia Pacific Automated Cell Counting Market by Country in 2022 and would continue to be a dominant market till 2030; thereby, achieving a market value of $643.7 million by 2030. The Japan market is registering a CAGR of 12.2% during (2023 - 2030). Additionally, The India market would showcase a CAGR of 13.7% during (2023 - 2030).
Based on Product, the market is segmented into Consumables Accessories, and Instruments (Image-based Cell Counters, Flow Cytometers, Electrical Impendence Coulter Counters). Based on Application, the market is segmented into Cell Line development, Blood Analysis, Stem Cell Research, and Others. Based on End-use, the market is segmented into Pharmaceutical Biotechnology Companies, Hospitals Diagnostic laboratories, Research Academic Institutes, and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Shanghai Ruiyu Biotechnology Co., Ltd. (Alit Biotech (Shanghai) Co., Ltd.), Thermo Fisher Scientific, Inc., Bio-Rad laboratories, Inc., F. Hoffmann-La Roche Ltd., Danaher Corporation, Olympus Corporation, Merck KGaA, Abbott Laboratories, Sysmex Corporation, and Agilent Technologies, Inc.
Technological innovation serves as the bedrock of this market's growth. Advancements in imaging technologies, microfluidics, artificial intelligence, and multiplexing capabilities continuously elevate these instruments' precision, speed, and capabilities. The COVID-19 pandemic acted as a catalyst, underscoring the indispensable role of cell analysis in virology, vaccine development, and immunology research. It also accelerated the adoption of remote monitoring and automated solutions, further highlighting the adaptability and resilience of these instruments in demanding and dynamic research environments.
Emerging trends such as integrating artificial intelligence (AI) and machine learning in cell analysis, miniaturization of instruments for point-of-care testing, and increased focus on personalized medicine further expand the market's scope, opening new opportunities for innovation and growth. AI algorithms in image-based cell measuring instruments improve accuracy by precisely identifying and counting cells, overcoming challenges related to variations in cell morphology and background noise.
The pharmaceutical industry's expanding emphasis on target research and drug discovery increases the need for automated cell counters. Preclinical lab testing of novel drug candidates and vaccines is essential to these systems. Numerous prominent pharmaceutical companies are implementing automated solutions to decrease drug development costs and schedules while accelerating their R D programs. Thus, the demand for automated cell counting systems is propelled by advancements in this region's pharmaceutical and biotechnology industries.
The China market dominated the Asia Pacific Automated Cell Counting Market by Country in 2022 and would continue to be a dominant market till 2030; thereby, achieving a market value of $643.7 million by 2030. The Japan market is registering a CAGR of 12.2% during (2023 - 2030). Additionally, The India market would showcase a CAGR of 13.7% during (2023 - 2030).
Based on Product, the market is segmented into Consumables Accessories, and Instruments (Image-based Cell Counters, Flow Cytometers, Electrical Impendence Coulter Counters). Based on Application, the market is segmented into Cell Line development, Blood Analysis, Stem Cell Research, and Others. Based on End-use, the market is segmented into Pharmaceutical Biotechnology Companies, Hospitals Diagnostic laboratories, Research Academic Institutes, and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Shanghai Ruiyu Biotechnology Co., Ltd. (Alit Biotech (Shanghai) Co., Ltd.), Thermo Fisher Scientific, Inc., Bio-Rad laboratories, Inc., F. Hoffmann-La Roche Ltd., Danaher Corporation, Olympus Corporation, Merck KGaA, Abbott Laboratories, Sysmex Corporation, and Agilent Technologies, Inc.
Scope of the Study
Market Segments Covered in the Report:
By Product
- Consumables Accessories
- Instruments
- Image-based Cell Counters
- Flow Cytometers
- Electrical Impendence Coulter Counters
By Application
- Cell Line development
- Blood Analysis
- Stem Cell Research
- Others
By End-use
- Pharmaceutical Biotechnology Companies
- Hospitals Diagnostic laboratories
- Research Academic Institutes
- Others
By Country
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Key Market Players
List of Companies Profiled in the Report:
- Shanghai Ruiyu Biotechnology Co., Ltd. (Alit Biotech (Shanghai) Co., Ltd.)
- Thermo Fisher Scientific, Inc.
- Bio-Rad laboratories, Inc.
- F.Hoffmann-La Roche Ltd.
- Danaher Corporation
- Olympus Corporation
- Merck KGaA
- Abbott Laboratories
- Sysmex Corporation
- Agilent Technologies, Inc.
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 4. Competition Analysis - Global
Chapter 5. Asia Pacific Automated Cell Counting Market by Product
Chapter 6. Asia Pacific Automated Cell Counting Market by Application
Chapter 7. Asia Pacific Automated Cell Counting Market by End-use
Chapter 8. Asia Pacific Automated Cell Counting Market by Country
Chapter 9. Company Profiles
Companies Mentioned
- Shanghai Ruiyu Biotechnology Co., Ltd. (Alit Biotech (Shanghai) Co., Ltd.)
- Thermo Fisher Scientific, Inc.
- Bio-Rad laboratories, Inc.
- F. Hoffmann-La Roche Ltd.
- Danaher Corporation
- Olympus Corporation
- Merck KGaA
- Abbott Laboratories
- Sysmex Corporation
- Agilent Technologies, Inc.
Methodology
LOADING...
